alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › approval

approval

2 studies tagged approval, dated 2024-01-01 to 2024-09-06. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Donanemab: First Approval 2024-09-06
  2. Lessons Learned from Approval of Aducanumab for Alzheimer's Disease 2024-01-01

Studies

2 studies carry this tag.

Date range

2024

Top journals

  • Annual review of medicine 1
  • Drugs 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Donanemab: First Approval

    ✓ Peer-reviewed alzhub usefulness score 41 out of 100. Drugs 2024-09-06 Treatments

    Donanemab (donanemab-azbt; Kisunla TM ) is an amyloid β-directed antibody developed by Eli Lilly and Company for the treatment of Alzheimer's disease.

  2. Lessons Learned from Approval of Aducanumab for Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 45 out of 100. Annual review of medicine 2024-01-01 Treatments

    When the US Food and Drug Administration used the accelerated approval process to authorize the use of the antiamyloid drug aducanumab to treat Alzheimer's disease (AD), many people hoped this signaled a new era of disease-modifying treatment.

All topic tags with their study counts